Valneva SE (EPA:VLA)
4.396
+0.140 (3.29%)
Jan 12, 2026, 11:43 AM CET
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M
Revenue Growth
+13.48%
P/S Ratio
4.09
Revenue / Employee
252.33K
Employees
713
Market Cap
735.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Valneva SE News
- 3 days ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 days ago - Valneva SE - Declaration of voting rights - December 2025 - GlobeNewsWire
- 11 days ago - Valneva (VALN) Ends Vaccine Licensing Deal with Serum Institute - GuruFocus
- 11 days ago - Valneva ends chikungunya vaccine deal with India’s Serum Institute - Seeking Alpha
- 11 days ago - Valneva (VALN) Reclaims Chikungunya Vaccine Rights to Enhance Global Reach - GuruFocus
- 11 days ago - Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement - GlobeNewsWire
- 4 weeks ago - Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine - GuruFocus
- 4 weeks ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire